PedAM
Pediatric Disease Annotations & Medicines
| lymphopenia | ||||
| Disease ID | 898 |
|---|---|
| Disease | lymphopenia |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:4) C0023530 | leucopenia | 3 C0021079 | immunosuppression | 2 C0027947 | neutropenia | 2 C0029118 | opportunistic infections | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:10) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0024312 | bortezomib | D000069286 | - | lymphopenia | MESH:D008231 | marker/mechanism | 20385792 | ||
| C0024312 | cladribine | D017338 | 4291-63-8 | lymphopenia | MESH:D008231 | marker/mechanism | 7850921 | ||
| C0024312 | crizotinib | C551994 | - | lymphopenia | MESH:D008231 | marker/mechanism | 22954507 | ||
| C0024312 | doxycycline | D004318 | 564-25-0 | lymphopenia | MESH:D008231 | marker/mechanism | 9145823 | ||
| C0024312 | ethosuximide | D005013 | 77-67-8 | lymphopenia | MESH:D008231 | marker/mechanism | 9776542 | ||
| C0024312 | gemcitabine | C056507 | 103882-84-4 | lymphopenia | MESH:D008231 | marker/mechanism | 22338014 | ||
| C0024312 | lenalidomide | C467567 | - | lymphopenia | MESH:D008231 | marker/mechanism | 20385792 | ||
| C0024312 | paclitaxel | D017239 | - | lymphopenia | MESH:D008231 | marker/mechanism | 7644923 | ||
| C0024312 | temozolomide | C047246 | 85622-93-1 | lymphopenia | MESH:D008231 | marker/mechanism | 17024124 | ||
| C0024312 | temsirolimus | C401859 | - | lymphopenia | MESH:D008231 | marker/mechanism | 16012795 | ||
FDA approved drug and dosage information(Total Drugs:4) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D008231 | temodar | temozolomide | 5MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D008231 | temodar | temozolomide | 100MG/VIAL | POWDER;INTRAVENOUS | Prescription | None | Yes | Yes |
| MESH:D008231 | torisel | temsirolimus | 25MG/ML (25MG/ML) | SOLUTION;INTRAVENOUS | Prescription | None | Yes | Yes |
| MESH:D008231 | velcade | bortezomib | 3.5MG/VIAL | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:4) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D008231 | 11/3/2003 | temodar | temozolomide | Recurrent CNS tumors | Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults | Labeling | B | - | - | - | Schering | 11/20/2002 | FALSE' |
| MESH:D008231 | 11/3/2003 | temodar | temozolomide | Recurrent CNS tumors | Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults | Labeling | B | - | - | - | Schering | 11/20/2002 | FALSE' |
| MESH:D008231 | 05/30/2012 | torisel | temsirolimus | Advanced recurrent/refractory solid tumors | Effectiveness in pediatric patients has not been established Torisel was studied in 59 patients 1 - 17 years and 12 patients 18 to 21 years in a phase 1-2 safety and exploratory pharmacodynamic study Adverse reactions were similar to those observedd in adults Information on dosing, clinical trials and PK parameters | Labeling | B | - | - | - | - | - | FALSE' |
| MESH:D008231 | 09/14/2015 | velcade | bortezomib | Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) | Effectiveness in pediatric patients with relapsed pre-B ALL has not been established. The activity and safety of Velcade in combination with intensive reinduction chemotherapy was evaluated in pediatric and young adult patients with lymphoid malignancies. There were 140 patients with ALL or LL enrolled and evaluated for safety. No new safety concerns were observed | Labeling | B | - | - | - | Millennium Pharmaceuticals, Inc. | - | FALSE |